ATE404189T1 - Statine zur behandlung von okularer hypertonie und glaukom - Google Patents

Statine zur behandlung von okularer hypertonie und glaukom

Info

Publication number: ATE404189T1
Authority: AT; Austria
Prior art keywords: statins; glaucoma; treatment; coa reductase; protect against
Prior art date: 2004-04-26

Application number

AT05738648T

Other languages

English (en)

Inventor

Mark Hellberg

Debra Fleenor

Allan Shepard

Iok-Hou Pang

Original Assignee

Alcon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-26

Filing date

2005-04-25

Publication date

2008-08-15

2005-04-25 Application filed by Alcon Inc filed Critical Alcon Inc

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE404189T1 publication Critical patent/ATE404189T1/de

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 5
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 5
208000010412 Glaucoma Diseases 0.000 title abstract 2
206010020772 Hypertension Diseases 0.000 title 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
208000017442 Retinal disease Diseases 0.000 abstract 1
206010038923 Retinopathy Diseases 0.000 abstract 1
230000004410 intraocular pressure Effects 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
230000000699 topical effect Effects 0.000 abstract 1
210000001585 trabecular meshwork Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrane Compounds (AREA)

AT05738648T 2004-04-26 2005-04-25 Statine zur behandlung von okularer hypertonie und glaukom ATE404189T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US56546904P	2004-04-26	2004-04-26

Publications (1)

Publication Number	Publication Date
ATE404189T1 true ATE404189T1 (de)	2008-08-15

Family

ID=34966865

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05738648T ATE404189T1 (de)	2004-04-26	2005-04-25	Statine zur behandlung von okularer hypertonie und glaukom

Country Status (19)

Country	Link
US (2)	US20050239871A1 (de)
EP (1)	EP1740164B1 (de)
JP (1)	JP2007534699A (de)
KR (2)	KR20110091600A (de)
CN (1)	CN1946384B (de)
AT (1)	ATE404189T1 (de)
AU (1)	AU2005237543B2 (de)
BR (1)	BRPI0510245A (de)
CA (1)	CA2560167A1 (de)
CY (1)	CY1108490T1 (de)
DE (1)	DE602005008935D1 (de)
DK (1)	DK1740164T3 (de)
ES (1)	ES2311986T3 (de)
MX (1)	MXPA06012225A (de)
PL (1)	PL1740164T3 (de)
PT (1)	PT1740164E (de)
SI (1)	SI1740164T1 (de)
WO (1)	WO2005105069A1 (de)
ZA (1)	ZA200607988B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007512347A (ja) *	2003-11-26	2007-05-17	デューク・ユニバーシティー	緑内障を予防するかまたは治療する方法
WO2007070866A2 (en) *	2005-12-16	2007-06-21	Alcon, Inc.	Control of intraocular pressure using alk5 modulation agents
ES2385752T3 (es)	2006-04-26	2012-07-31	Rosemont Pharmaceuticals Ltd	Composiciones orales líquidas
US20090202524A1 (en) *	2007-10-31	2009-08-13	Alcon Research, Ltd.	Pai-1 expression and activity inhibitors for the treatment of ocular disorders
ES2330184B1 (es) *	2008-06-03	2010-07-05	Neuron Biopharma, S.A.	Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
US20110293549A1 (en)	2009-02-03	2011-12-01	Athena Cosmetics, Inc.	Composition, method and kit for enhancing hair
US8299079B2 (en)	2009-05-22	2012-10-30	Kaufman Herbert E	Preparations and methods for ameliorating or reducing presbyopia
CN102093984B (zh) *	2010-11-23	2012-07-04	清华大学	一种杂合酶P450sca2-BMR及其编码基因与应用
AU2013214693B2 (en)	2012-02-02	2017-02-23	Kenneth Gek-Jin OOI	Improvements in tear film stability
GB201611782D0 (en) *	2016-07-06	2016-08-17	Optibiotix Ltd	Composition
US10696638B2 (en)	2017-12-26	2020-06-30	Industrial Technology Research Institute	Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2025147589A1 (en) *	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2534580A1 (fr) *	1982-10-13	1984-04-20	Synthelabo	Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
FR2585708B1 (fr) *	1985-07-31	1989-07-07	Sanofi Sa	Derives aminoalcools peptidiques inhibiteurs de la resine et des proteases acides, leur procede de preparation et leur application en therapeutique
US5151444B1 (en) *	1987-09-18	1999-07-06	R Tech Ueno Ltd	Ocular hypotensive agents
US5296504A (en) *	1988-09-06	1994-03-22	Kabi Pharmacia	Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1348437A3 (de) *	1988-09-06	2003-11-19	Pharmacia Aktiebolag	Prostaglandinderivative zur Behandlung von Glaukoma oder okuläre Hypertension
FR2647675B1 (fr) *	1989-06-05	1994-05-20	Sanofi	Utilisation d'un derive de la statine dans le traitement des affections oculaires
JPH04243835A (ja) *	1990-08-29	1992-08-31	Pfizer Inc	高眼圧症又は緑内障治療用薬剤組成物及び治療方法
US5352708A (en) *	1992-09-21	1994-10-04	Allergan, Inc.	Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) *	1993-08-03	1996-04-23	Alcon Laboratories, Inc.	Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5599535A (en) *	1995-06-07	1997-02-04	Regents Of The University Of California	Methods for the cyto-protection of the trabecular meshwork
US6586425B2 (en) *	1996-02-21	2003-07-01	Wisconsin Alumni Research Foundation	Cytoskeletal active agents for glaucoma therapy
US6569461B1 (en) *	1999-03-08	2003-05-27	Merck & Co., Inc.	Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
WO2002024194A2 (en) *	2000-09-19	2002-03-28	Novimmune S.A.	Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US20030065020A1 (en) *	2001-07-13	2003-04-03	Catharine Gale	Treatment of macular degeneration
US20030195167A1 (en) *	2002-04-15	2003-10-16	Kowa Co., Ltd.	PTX3-gene expression inhibitor
JP2004149480A (ja) *	2002-10-31	2004-05-27	Saisentan Igaku Kenkyusho:Kk	経口又は経皮投与用の眼科疾患治療剤
US20040248972A1 (en) *	2003-05-16	2004-12-09	Ambit Biosciences Corporation	Compounds and uses thereof
WO2004110998A1 (en) *	2003-05-16	2004-12-23	Ambit Biosciences Corporation	Pyrrole compounds and uses thereof
WO2005000208A2 (en) *	2003-05-30	2005-01-06	Combinatorx, Inc.	Combination therapy for the treatment of neoplasms
JP2007512347A (ja) *	2003-11-26	2007-05-17	デューク・ユニバーシティー	緑内障を予防するかまたは治療する方法
US20090202524A1 (en) *	2007-10-31	2009-08-13	Alcon Research, Ltd.	Pai-1 expression and activity inhibitors for the treatment of ocular disorders

2005
- 2005-04-25 MX MXPA06012225A patent/MXPA06012225A/es active IP Right Grant
- 2005-04-25 ES ES05738648T patent/ES2311986T3/es not_active Expired - Lifetime
- 2005-04-25 DK DK05738648T patent/DK1740164T3/da active
- 2005-04-25 PT PT05738648T patent/PT1740164E/pt unknown
- 2005-04-25 KR KR1020117018000A patent/KR20110091600A/ko not_active Withdrawn
- 2005-04-25 BR BRPI0510245-6A patent/BRPI0510245A/pt not_active IP Right Cessation
- 2005-04-25 US US11/114,512 patent/US20050239871A1/en not_active Abandoned
- 2005-04-25 JP JP2007509736A patent/JP2007534699A/ja active Pending
- 2005-04-25 ZA ZA200607988A patent/ZA200607988B/xx unknown
- 2005-04-25 AT AT05738648T patent/ATE404189T1/de active
- 2005-04-25 WO PCT/US2005/014255 patent/WO2005105069A1/en not_active Ceased
- 2005-04-25 AU AU2005237543A patent/AU2005237543B2/en not_active Ceased
- 2005-04-25 DE DE602005008935T patent/DE602005008935D1/de not_active Expired - Lifetime
- 2005-04-25 SI SI200530460T patent/SI1740164T1/sl unknown
- 2005-04-25 EP EP05738648A patent/EP1740164B1/de not_active Expired - Lifetime
- 2005-04-25 CA CA002560167A patent/CA2560167A1/en not_active Abandoned
- 2005-04-25 CN CN2005800130061A patent/CN1946384B/zh not_active Expired - Fee Related
- 2005-04-25 PL PL05738648T patent/PL1740164T3/pl unknown
2006
- 2006-11-15 KR KR1020067023958A patent/KR101071192B1/ko not_active Expired - Fee Related
2008
- 2008-11-07 CY CY20081101271T patent/CY1108490T1/el unknown
2010
- 2010-11-08 US US12/941,639 patent/US20110098314A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1740164B1 (de)	2008-08-13
DK1740164T3 (da)	2008-11-10
PT1740164E (pt)	2008-10-21
PL1740164T3 (pl)	2009-01-30
CY1108490T1 (el)	2014-04-09
JP2007534699A (ja)	2007-11-29
KR20070007932A (ko)	2007-01-16
DE602005008935D1 (de)	2008-09-25
KR20110091600A (ko)	2011-08-11
KR101071192B1 (ko)	2011-10-10
SI1740164T1 (sl)	2009-02-28
MXPA06012225A (es)	2007-01-31
US20110098314A1 (en)	2011-04-28
CA2560167A1 (en)	2005-11-10
BRPI0510245A (pt)	2007-10-23
EP1740164A1 (de)	2007-01-10
AU2005237543B2 (en)	2011-02-10
AU2005237543A1 (en)	2005-11-10
CN1946384A (zh)	2007-04-11
US20050239871A1 (en)	2005-10-27
ZA200607988B (en)	2007-12-27
WO2005105069A1 (en)	2005-11-10
HK1102913A1 (en)	2007-12-07
CN1946384B (zh)	2011-04-20
ES2311986T3 (es)	2009-02-16

Legal Events

Date

Code

Title

Description

2009-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1740164

Country of ref document: EP

Publication	Publication Date	Title
CY1108490T1 (el)	2014-04-09	Στατινες για την αντιμετωπιση της οφθαλμικης υπερτασης και του γλαυκωματος
WO2006066103A3 (en)	2006-09-08	Ophthalmic implant for treatment of glaucoma
ATE480240T1 (de)	2010-09-15	Zusammensetzung enthaltend latanoprost und behandlungsmethode von erhöhtem augeninnendruck und glaukom
ATE303757T1 (de)	2005-09-15	Behandlung von augenerkrankungen
WO2007076360A8 (en)	2007-12-06	(indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
CY1108651T1 (el)	2014-04-09	Προληπτικος ή θεραπευτικος παραγων για γλαυκωμα
ATE359794T1 (de)	2007-05-15	3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ATE453395T1 (de)	2010-01-15	3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
TW200501949A (en)	2005-01-16	Ophthalmic compositions for treating ocular hypertension
WO2005020917A3 (en)	2005-05-19	Ophthalmic compositions for treating ocular hypertension
HK1045645A1 (zh)	2002-12-06	消除角膜瘢痕、浑浊化和混浊的生化方法
EP1488808A4 (de)	2007-05-23	Mittel zur behandlung von glomerulären erkrankungen
WO2004043354A3 (en)	2004-08-26	Ophthalmic compositions for treating ocular hypertension
DE60135972D1 (de)	2008-11-13	Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
BR0215172A (pt)	2004-10-19	Derivados de benzodifuranimidazolina e benzofuranimidazolina e seu emprego para o tratamento de glaucoma
MXPA04001255A (es)	2004-05-27	Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
WO2007045930A3 (en)	2007-07-12	Modulation of trpv expression levels
ATE270883T1 (de)	2004-07-15	Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck
UA86346C2 (ru)	2009-04-27	Способ лечения открытоугольной глаукомы